Prognosis following interventional therapy for acute mycardial infarction: Utility of dipyridamole thallium scintigraphy

Robert Hendel, J. M. Gore, J. S. Alpert, J. A. Leppo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A variety of methods for risk stratification after acute myocardial infarction have been successfully employed, however, little attention has been focused on patients who have received reperfusion therapy. The present report examines the utility of dipyridamole thallium scintigraphy in the prediction of late cardiac death or recurrent myocardial infarction in patients who have received thrombolytic therapy. Prospectively, 71 patients who presented with myocardial infarction and were treated with recombinant tissue plasminogen activator (and frequently percutaneous transluminal coronary angioplasty) were enrolled in the study. The primary end points during the follow-up period of nearly 2 years were recurrent infarction or death, which occurred in 10 patients. Although cardiac events were significantly related to either the performance of late myocardial revascularization or the presence of a residual coronary artery stenosis at discharge, no scintigraphic variable was found to be predictive of myocardial infarction or death. Thus, this report is the first to suggest limitation of scintigraphic techniques with regard to prognostic value in myocardial infarction survivors treated with reperfusion techniques. This selected population may have physiologic differences as compared with post-infarction studies performed before the advent of thrombolytic agents. Caution is therefore advised in extrapolating results of earlier reports to the ever increasing percentage of patients receiving recannalization therapy.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalCardiology
Volume79
Issue number1
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Dipyridamole
Thallium
Radionuclide Imaging
Infarction
Myocardial Infarction
Reperfusion
Therapeutics
Myocardial Revascularization
Coronary Balloon Angioplasty
Fibrinolytic Agents
Coronary Stenosis
Thrombolytic Therapy
Tissue Plasminogen Activator
Survivors
Population

Keywords

  • dipyridamole
  • thallium
  • thrombolytic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognosis following interventional therapy for acute mycardial infarction : Utility of dipyridamole thallium scintigraphy. / Hendel, Robert; Gore, J. M.; Alpert, J. S.; Leppo, J. A.

In: Cardiology, Vol. 79, No. 1, 01.01.1991, p. 73-80.

Research output: Contribution to journalArticle

Hendel, Robert ; Gore, J. M. ; Alpert, J. S. ; Leppo, J. A. / Prognosis following interventional therapy for acute mycardial infarction : Utility of dipyridamole thallium scintigraphy. In: Cardiology. 1991 ; Vol. 79, No. 1. pp. 73-80.
@article{c4bf7d5c901b4aa581cb5a8931f55a0b,
title = "Prognosis following interventional therapy for acute mycardial infarction: Utility of dipyridamole thallium scintigraphy",
abstract = "A variety of methods for risk stratification after acute myocardial infarction have been successfully employed, however, little attention has been focused on patients who have received reperfusion therapy. The present report examines the utility of dipyridamole thallium scintigraphy in the prediction of late cardiac death or recurrent myocardial infarction in patients who have received thrombolytic therapy. Prospectively, 71 patients who presented with myocardial infarction and were treated with recombinant tissue plasminogen activator (and frequently percutaneous transluminal coronary angioplasty) were enrolled in the study. The primary end points during the follow-up period of nearly 2 years were recurrent infarction or death, which occurred in 10 patients. Although cardiac events were significantly related to either the performance of late myocardial revascularization or the presence of a residual coronary artery stenosis at discharge, no scintigraphic variable was found to be predictive of myocardial infarction or death. Thus, this report is the first to suggest limitation of scintigraphic techniques with regard to prognostic value in myocardial infarction survivors treated with reperfusion techniques. This selected population may have physiologic differences as compared with post-infarction studies performed before the advent of thrombolytic agents. Caution is therefore advised in extrapolating results of earlier reports to the ever increasing percentage of patients receiving recannalization therapy.",
keywords = "dipyridamole, thallium, thrombolytic therapy",
author = "Robert Hendel and Gore, {J. M.} and Alpert, {J. S.} and Leppo, {J. A.}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "79",
pages = "73--80",
journal = "Cardiology (Switzerland)",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Prognosis following interventional therapy for acute mycardial infarction

T2 - Utility of dipyridamole thallium scintigraphy

AU - Hendel, Robert

AU - Gore, J. M.

AU - Alpert, J. S.

AU - Leppo, J. A.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - A variety of methods for risk stratification after acute myocardial infarction have been successfully employed, however, little attention has been focused on patients who have received reperfusion therapy. The present report examines the utility of dipyridamole thallium scintigraphy in the prediction of late cardiac death or recurrent myocardial infarction in patients who have received thrombolytic therapy. Prospectively, 71 patients who presented with myocardial infarction and were treated with recombinant tissue plasminogen activator (and frequently percutaneous transluminal coronary angioplasty) were enrolled in the study. The primary end points during the follow-up period of nearly 2 years were recurrent infarction or death, which occurred in 10 patients. Although cardiac events were significantly related to either the performance of late myocardial revascularization or the presence of a residual coronary artery stenosis at discharge, no scintigraphic variable was found to be predictive of myocardial infarction or death. Thus, this report is the first to suggest limitation of scintigraphic techniques with regard to prognostic value in myocardial infarction survivors treated with reperfusion techniques. This selected population may have physiologic differences as compared with post-infarction studies performed before the advent of thrombolytic agents. Caution is therefore advised in extrapolating results of earlier reports to the ever increasing percentage of patients receiving recannalization therapy.

AB - A variety of methods for risk stratification after acute myocardial infarction have been successfully employed, however, little attention has been focused on patients who have received reperfusion therapy. The present report examines the utility of dipyridamole thallium scintigraphy in the prediction of late cardiac death or recurrent myocardial infarction in patients who have received thrombolytic therapy. Prospectively, 71 patients who presented with myocardial infarction and were treated with recombinant tissue plasminogen activator (and frequently percutaneous transluminal coronary angioplasty) were enrolled in the study. The primary end points during the follow-up period of nearly 2 years were recurrent infarction or death, which occurred in 10 patients. Although cardiac events were significantly related to either the performance of late myocardial revascularization or the presence of a residual coronary artery stenosis at discharge, no scintigraphic variable was found to be predictive of myocardial infarction or death. Thus, this report is the first to suggest limitation of scintigraphic techniques with regard to prognostic value in myocardial infarction survivors treated with reperfusion techniques. This selected population may have physiologic differences as compared with post-infarction studies performed before the advent of thrombolytic agents. Caution is therefore advised in extrapolating results of earlier reports to the ever increasing percentage of patients receiving recannalization therapy.

KW - dipyridamole

KW - thallium

KW - thrombolytic therapy

UR - http://www.scopus.com/inward/record.url?scp=0025913543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025913543&partnerID=8YFLogxK

M3 - Article

C2 - 1777916

AN - SCOPUS:0025913543

VL - 79

SP - 73

EP - 80

JO - Cardiology (Switzerland)

JF - Cardiology (Switzerland)

SN - 0008-6312

IS - 1

ER -